The General Hospital Corporation;Genzyme Corporation
发明人:
Streisand, James B.,Roberts, Jesse D.
申请号：
DK15154393
公开号：
DK2918288T3
申请日:
2007.10.03
申请国别(地区):
DK
年份:
2017
代理人:
摘要：
The disclosure relates to methods of treating an infant at risk of developing bronchopulmonary dysplasia, including premature infants, by administering a TGF-² antagonist during the perinatal period, including the prenatal period and/or the postnatal period. For administration during the prenatal period, the TGF-² antagonist can be administered either directly to the infant in utero, or indirectly by administration to the mother.
